"Signaling Through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity"

Recorded live on Tuesday, May 19th, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted by the Community of Transplant Scientists (COTS)

"Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity"
(Immunity. 2020 Jan 14;52(1):136-150.e6. doi: 10.1016/j.immuni.2019.12.006.)

In this article:
"Effector CD8+ T cells are important mediators of adaptive immunity, and receptor-ligand interactions that regulate their survival may have therapeutic potential. Here, [the authors] identified a subset of effector CD8+ T cells that expressed the inhibitory fragment crystallizable (Fc) receptor FcγRIIB following activation and multiple rounds of division... Increased expression of FcγRIIB correlated with freedom from rejection following withdrawal from immunosuppression in a clinical trial of kidney transplant recipients. [Findings demonstrated] a cell-intrinsic coinhibitory function of FcγRIIB in regulating CD8+ T cell immunity."

Anna Morris, PhD • Emory University, Atlanta, GA
Mandy Ford, PhD • Emory University, Atlanta, GA

Olivia Martinez, PhD • Stanford University, Stanford, CA

Watch Video

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.